Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Prostatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Leukemia 1Healthy Volunteer 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × keyhole-limpet hemocyanin × Clear all
NCT00124124 2015-02-13

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Bhardwaj, Nina, M.D.

Phase 1 Completed
50 enrolled
Dermatologic

Melanoma

NCT00091143 2013-04-04

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡